Reading the tape
NASDAQ: EWTX
Edgewise Therapeutics, Inc.
Healthcare · Biotechnology
Market Cap
$3.37B
52w High
$35.00
52w Low
$12.15
P/E
-19.29
Volume
642.27K
Outstanding Shares
107.27M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 90.15%FCF (TTM): -30.34%
What changed
The stock rose 90.15% over the last year. Free cash flow declined 30.34% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
A decisive shift in revenue or cash flow over the next period would be the clearest signal to resolve the ambiguity.
Company profile
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases.
CEOKevin Koch
SectorHealthcare
IndustryBiotechnology
Employees117
IPO dateMar 26, 2021
Valuation
Forward P/E—
EV/EBITDA-15.09
Enterprise value$2.5B
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth—
Gross margin0%
Operating margin0%
ROE-32.13%▼10.26%vs FY2024
Analyst consensus
RatingBuy
Target price$38.67▲22.96%
7
Buy
1
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
Q2 FY26 · EPS est -$0.50 · Revenue est —
View